GuidelineArthritis & rheumatology (Hoboken, N.J.)2023
2022 American College of Rheumatology Guideline for Vaccinations in Patients With Rheumatic and Musculoskeletal Diseases.
Guideline in Arthritis & rheumatology (Hoboken, N.J.), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 2 syntheses or guidelines pooled it, 57 citations in OpenAlex.
- Brazilian Society of Rheumatology - 2025 recommendations on vaccination in immune-mediated rheumatic diseases.Advances in rheumatology (London, England) · 2026Guideline
- Saudi National Clinical Practice Guidelines for Management of Adult Systemic Lupus Erythematosus.Current rheumatology reviews · 2025Guideline
- Evaluation of the Safety of Recombinant Zoster Vaccine on Patients with Systemic Lupus Erythematosus in a Tertiary Hospital in Saudi Arabia: A Retrospective Single Centre Study.Mediterranean journal of rheumatology · 2026Article
- Translating B-Cell and Plasma-Cell Targeting from Oncology to Autoimmunity: Modalities, Quantitative Bridging, and a Development Roadmap.Clinical pharmacology and therapeutics · 2026Review
- Identification of Invasive Aspergillosis in Electronic Health Records.Open forum infectious diseases · 2026Article
- Risk of herpes zoster among adults in the United States initiating immunosuppressive therapy: A retrospective cohort study.Journal of managed care & specialty pharmacy · 2026Article
- Variability in vaccination practices in children with rheumatic diseases: results of a childhood arthritis and rheumatology research alliance (CARRA)-wide survey.Pediatric rheumatology online journal · 2026Article
- Herpes zoster vaccination uptake in rheumatic diseases: persistent implementation gap despite improved uptake.Rheumatology advances in practice · 2026Article
- Advances in the pathophysiology, diagnosis and treatment of Takayasu arteritis.Nature reviews. Rheumatology · 2025Review
- Effectiveness and safety of the recombinant zoster vaccine in adults aged ≥50 years with inflammatory bowel disease.Human vaccines & immunotherapeutics · 2025Article
- Lupus nephritis.Nature reviews. Disease primers · 2025Review
- Vaccination Update and Specific Concerns for RA.Current rheumatology reports · 2025Review
- 2025 Chinese guidelines for the diagnosis and treatment of systemic lupus erythematosus.Rheumatology and immunology research · 2025Article
- Top ten tips in managing ANCA vasculitis.Clinical kidney journal · 2025Review
- Infection Screening and Vaccination of Adult and Pediatric Patients with Autoimmune Inflammatory Rheumatic Diseases: An Emirati Delphi Consensus.Current rheumatology reviews · 2025Review
- Recombinant Zoster Vaccination Among US Veterans Receiving Immunosuppressive Medications.JAMA network open · 2024Article
- Inflammatory turmoil within: an exploration of autoinflammatory disease genetic underpinnings, clinical presentations, and therapeutic approaches.Advances in rheumatology (London, England) · 2024Review
- Defining the key clinician skills and attributes for competency in managing patients with osteoporosis and fragility fractures.Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research · 2024Article
- Additional Reassuring Data for SARS-CoV-2 Vaccination in Immune-Mediated Inflammatory Diseases, but With a Catch.The Journal of rheumatology · 2024Article
- Treatment of Granulomatous Inflammation in Pulmonary Sarcoidosis.Journal of clinical medicine · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
41 authors at 20 institutions in 3 countries.
Funding
Abstract
objectiveTo provide evidence-based recommendations on the use of vaccinations in children and adults with rheumatic and musculoskeletal diseases (RMDs).
methodsThis guideline follows American College of Rheumatology (ACR) policy guiding management of conflicts of interest and disclosures and the ACR guideline development process, which includes the Grading of Recommendations Assessment, Development and Evaluation (GRADE) methodology. It also adheres to the Appraisal of Guidelines for Research and Evaluation (AGREE) criteria. A core leadership team consisting of adult and pediatric rheumatologists and a guideline methodologist drafted clinical population, intervention, comparator, outcomes (PICO) questions. A review team performed a systematic literature review for the PICO questions, graded the quality of evidence, and produced an evidence report. An expert Voting Panel reviewed the evidence and formulated recommendations. The panel included adult and pediatric rheumatology providers, infectious diseases specialists, and patient representatives. Consensus required ≥70% agreement on both the direction and strength of each recommendation.
resultsThis guideline includes expanded indications for some vaccines in patients with RMDs, as well as guidance on whether to hold immunosuppressive medications or delay vaccination to maximize vaccine immunogenicity and efficacy. Safe approaches to the use of live attenuated vaccines in patients taking immunosuppressive medications are also addressed. Most recommendations are conditional and had low quality of supporting evidence.
conclusionApplication of these recommendations should consider patients' individual risk for vaccine-preventable illness and for disease flares, particularly if immunosuppressive medications are held for vaccination. Shared decision-making with patients is encouraged in clinical settings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.